| Total (2010–2015) N = 1264 | Period 1 (2010–2011) N = 395 | Period 2 (2012–2013) N = 471 | Period 3 (2014–2015) N = 398 | P-value |
---|---|---|---|---|---|
Mean observation period, days (SD) | 469 (255) | 464 (247) | 476 (256) | 469 (261) | 0.76 |
Male, n (%) | 1242 (98.3) | 388 (98.2) | 460 (97.7) | 394 (99.0) | 0.33 |
Mean age at presentation, years (SD) | 29.43 (9.50) | 29.87 (10.18) | 29.61 (9.81) | 28.79 (8.33) | 0.25 |
Diagnoses of HIV due to active HIV surveillance, n (%) | 653 (49.7) | 188 (45.6) | 257 (52.7) | 208 (50.3) | 0.12 |
 VCT | 500 (39.6) | 132 (33.4) | 197 (41.8) | 171 (43.0) | 0.01 |
 Military screening | 124 (9.8) | 47 (11.9) | 50 (10.6) | 27 (6.8) | 0.04 |
 Screening at blood donation | 28 (2.3) | 9(2.1) | 10 (2.3) | 9 (2.2) | 0.99 |
 Prenatal screening | 1 (0.1) | 0 (0.0) | 0 (0.0) | 1 (0.3) | 0.34 |
HIV transmission route, n (%) | |||||
 Homosexual | 1031 (81.6) | 317 (80.3) | 376 (79.8) | 338 (84.9) | 0.11 |
 Heterosexual | 141 (11.2) | 56 (14.2) | 51 (10.8) | 34 (8.5) | 0.04 |
 Bisexual | 71 (5.6) | 17 (4.3) | 39 (8.3) | 15 (3.8) | 0.006 |
 IDU | 14 (1.1) | 3 (0.8) | 4 (0.8) | 7 (1.8) | 0.32 |
 Unknown | 7 (0.6) | 2 (0.5) | 1 (0.2) | 4 (1.0) | 0.29 |
Comorbidities, n (%) | |||||
 Chronic kidney disease | 6 (0.5) | 1 (0.3) | 2 (0.4) | 3 (0.8) | 0.58 |
 DM | 23 (1.8) | 10 (2.5) | 6 (1.3) | 7 (1.8) | 0.38 |
 Solid tumor | 11 (0.9) | 5 (1.3) | 5 (1.1) | 1 (0.3) | 0.26 |
 Autoimmune disease | 7 (0.6) | 3 (0.8) | 3 (0.6) | 1 (0.3) | 0.60 |
Mean CD4 count at presentation, cells/L (SD)a | 275 (205) | 271 (198) | 264 (208) | 293 (207) | 0.09 |
Subgroup of CD4 cell count at presentation, n (%)a | |||||
 CD4 cell count < 200 cells/μL | 491 (38.8) | 154 (39.0) | 189 (40.1) | 148 (37.2) | 0.67 |
 CD4 cell count 200–499 cells/μL | 612 (48.4) | 199 (50.4) | 226 (48.0) | 187 (47.0) | 0.62 |
 CD4 cell count ≥500 cells/μL | 161 (12.7) | 42 (10.6) | 56 (11.9) | 63 (15.8) | 0.07 |
Mean VL (log) (SD)a | 4.79 (0.83) | 4.78 (0.90) | 4.80 (0.85) | 4.78 (0.73) | 0.96 |
HIV VL > 100,000 copies/mL, n (%)a | 482 (38.1) | 160 (40.5) | 179 (38.0) | 143 (35.9) | 0.50 |
HBsAg seropositivity, n (%) | 117 (9.3) | 44 (11.1) | 41 (8.7) | 32 (8.0) | 0.28 |
HCV seropositivity, n (%) | 19 (4.8) | 8 (1.7) | 15 (3.8) | 42 (3.3) | 0.033 |
HIV stage at presentation by 2014 CDC definition [29], n (%) | |||||
 Stage 0 (Acute HIV) | 100 (7.9) | 38 (9.6) | 34 (7.2) | 28 (7.0) | 0.32 |
 Stage 1 (CD4 count ≥500 cells/μL) | 141 (11.2) | 37 (9.4) | 51 (10.8) | 53 (13.3) | 0.20 |
 Stage 2 (CD4 count 200–499 cells/μL) | 546 (43.2) | 168 (42.5) | 205 (43.5) | 173 (43.5) | 0.95 |
 Stage 3 (AOIs or CD4 cell count < 200 cells/μL) | 477 (37.7) | 152 (38.5) | 181 (38.4) | 144 (36.2) | 0.74 |
AOIs during observation period, n (%) | |||||
 Patients with AOI(s) at HIV presentation | 233 (18.4) | 77 (19.5) | 87 (18.5) | 69 (17.3) | 0.74 |
 Patients who developed AOI(s) within study period | 266 (21.0) | 89 (22.5) | 99 (21.0) | 78 (19.6) | 0.60 |
Mortality during observation period, n (%) | |||||
 AOI-related mortality | 47 (3.7) | 13 (3.3) | 22 (4.7) | 12 (3.0) | 0.38 |
 All-cause mortality | 56 (4.4) | 17 (4.3) | 27 (5.7) | 12 (3.0) | 0.15 |